EGFR-mutated Stage IV Non-small Cell Lung Cancer: What is the Role of Radiotherapy Combined with TKI?

Overview

Journal Cancer Med

Specialty Oncology

Date 2021 Aug 10

PMID 34374490

Citations 7

Authors

Bailong Liu

Hui Liu

Yunfei Ma

Qiuhui Ding

Min Zhang

Xinliang Liu

Min Liu

Affiliations

Soon will be listed here.

Abstract

Lung cancer is the leading cause of cancer-related death globally and poses a considerable threat to public health. Asia has the highest prevalence of epidermal growth factor receptor (EGFR) mutations in patients with non-small cell lung cancer (NSCLC). Despite the reasonable response and prolonged survival associated with EGFR-tyrosine kinase inhibitor (TKI) therapy, the acquisition of resistance to TKIs remains a major challenge. Additionally, patients with EGFR mutations are at a substantially higher risk of brain metastasis compared with those harboring wild-type EGFR. The role of radiotherapy (RT) in EGFR-mutated (EGFRm) stage IV NSCLC requires clarification, especially with the advent of next-generation TKIs, which are more potent and exhibit greater central nervous system activity. In particular, the feasible application of RT, including the timing, site, dose, fraction, and combination with TKI, merits further investigation. This review focuses on these key issues, and provides a flow diagram with proposed treatment options for metastatic EGFRm NSCLC, aiming to provide guidance for clinical practice.

Citing Articles

Optimizing Osimertinib for NSCLC: Targeting Resistance and Exploring Combination Therapeutics.

Liao Y, Tsai C, Huang H Cancers (Basel). 2025; 17(3).

PMID: 39941826 PMC: 11815769. DOI: 10.3390/cancers17030459.

Early stereotactic body radiation therapy improves progression-free survival of first-generation EGFR tyrosine kinase inhibitors in EGFR-mutated lung cancer: an observational cohort study.

Xu H, Qi R, Zhou C, Yu Y, Lin L, Wu X Ther Adv Med Oncol. 2024; 16:17588359241290133.

PMID: 39502405 PMC: 11536526. DOI: 10.1177/17588359241290133.

Single-cell transcriptomic sequencing data reveal aberrant DNA methylation in SMAD3 promoter region in tumor-associated fibroblasts affecting molecular mechanism of radiosensitivity in non-small cell lung cancer.

Han F, Chen S, Zhang K, Zhang K, Wang M, Wang P J Transl Med. 2024; 22(1):288.

PMID: 38493128 PMC: 10944599. DOI: 10.1186/s12967-024-05057-2.

Exploration of radiotherapy strategy for brain metastasis patients with driver gene positivity in lung cancer.

Bi Q, Lian X, Shen J, Zhang F, Xu T J Cancer. 2024; 15(7):1994-2002.

PMID: 38434971 PMC: 10905398. DOI: 10.7150/jca.91875.

Impact of thoracic tumor radiotherapy on survival in non-small-cell lung cancer with malignant pleural effusion treated with targeted therapy: Propensity score matching study.

Li Q, Hu C, Su S, Ma Z, Geng Y, Hu Y Cancer Med. 2023; 12(14):14949-14959.

PMID: 37288833 PMC: 10417183. DOI: 10.1002/cam4.6130.

References

Zhuang H, Hou H, Yuan Z, Wang J, Pang Q, Zhao L . Preliminary analysis of the risk factors for radiation pneumonitis in patients with non-small-cell lung cancer treated with concurrent erlotinib and thoracic radiotherapy. Onco Targets Ther. 2014; 7:807-13. PMC: 4043804. DOI: 10.2147/OTT.S62707. View

Tanaka T, Munshi A, Brooks C, Liu J, Hobbs M, Meyn R . Gefitinib radiosensitizes non-small cell lung cancer cells by suppressing cellular DNA repair capacity. Clin Cancer Res. 2008; 14(4):1266-73. PMC: 3385646. DOI: 10.1158/1078-0432.CCR-07-1606. View

van Vulpen M, Kal H, Taphoorn M . Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? (Review). Oncol Rep. 2002; 9(4):683-8. View

Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J . Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2009; 11(2):121-8. DOI: 10.1016/S1470-2045(09)70364-X. View

Soria J, Wu Y, Nakagawa K, Kim S, Yang J, Ahn M . Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol. 2015; 16(8):990-8. DOI: 10.1016/S1470-2045(15)00121-7. View

Chen C, Lee H, Chuang H, Hung J, Huang M, Chong I . Combination of Whole-Brain Radiotherapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Improves Overall Survival in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases. Cancers (Basel). 2019; 11(8). PMC: 6721307. DOI: 10.3390/cancers11081092. View

Yoshida T, Yoh K, Niho S, Umemura S, Matsumoto S, Ohmatsu H . RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation. Lung Cancer. 2015; 90(3):477-83. DOI: 10.1016/j.lungcan.2015.09.025. View

Oya Y, Yoshida T, Kuroda H, Shimizu J, Horio Y, Sakao Y . Association Between EGFR T790M Status and Progression Patterns During Initial EGFR-TKI Treatment in Patients Harboring EGFR Mutation. Clin Lung Cancer. 2017; 18(6):698-705.e2. DOI: 10.1016/j.cllc.2017.05.004. View

Han J, Park K, Kim S, Lee D, Kim H, Kim H . First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol. 2012; 30(10):1122-8. DOI: 10.1200/JCO.2011.36.8456. View

10.

Byeon S, Ham J, Sun J, Lee S, Ahn J, Park K . Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis. Med Oncol. 2016; 33(8):97. PMC: 4958121. DOI: 10.1007/s12032-016-0811-3. View

11.

De Ruysscher D, Wanders R, van Baardwijk A, Dingemans A, Reymen B, Houben R . Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450). J Thorac Oncol. 2012; 7(10):1547-55. DOI: 10.1097/JTO.0b013e318262caf6. View

12.

Liu B, Liu H, Ma Y, Ding Q, Zhang M, Liu X . EGFR-mutated stage IV non-small cell lung cancer: What is the role of radiotherapy combined with TKI?. Cancer Med. 2021; 10(18):6167-6188. PMC: 8446557. DOI: 10.1002/cam4.4192. View

13.

Saida Y, Watanabe S, Abe T, Shoji S, Nozaki K, Ichikawa K . Efficacy of EGFR-TKIs with or without upfront brain radiotherapy for EGFR-mutant NSCLC patients with central nervous system metastases. Thorac Cancer. 2019; 10(11):2106-2116. PMC: 6825912. DOI: 10.1111/1759-7714.13189. View

14.

Miyawaki E, Kenmotsu H, Mori K, Harada H, Mitsuya K, Mamesaya N . Optimal Sequence of Local and EGFR-TKI Therapy for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases Stratified by Number of Brain Metastases. Int J Radiat Oncol Biol Phys. 2019; 104(3):604-613. DOI: 10.1016/j.ijrobp.2019.02.051. View

15.

Das A, Chen B, Story M, Sato M, Minna J, Chen D . Somatic mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) abrogate EGFR-mediated radioprotection in non-small cell lung carcinoma. Cancer Res. 2007; 67(11):5267-74. DOI: 10.1158/0008-5472.CAN-07-0242. View

16.

Chen G, Feng J, Zhou C, Wu Y, Liu X, Wang C . Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC). Ann Oncol. 2013; 24(6):1615-22. DOI: 10.1093/annonc/mdt012. View

17.

Ballard P, Yates J, Yang Z, Kim D, Yang J, Cantarini M . Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity. Clin Cancer Res. 2016; 22(20):5130-5140. DOI: 10.1158/1078-0432.CCR-16-0399. View

18.

Chang C, Chi K, Kao S, Hsu P, Tsang Y, Chang H . Upfront gefitinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: a mono-institutional experience. Lung Cancer. 2011; 73(2):189-94. DOI: 10.1016/j.lungcan.2010.12.007. View

19.

Asami K, Okuma T, Hirashima T, Kawahara M, Atagi S, Kawaguchi T . Continued treatment with gefitinib beyond progressive disease benefits patients with activating EGFR mutations. Lung Cancer. 2012; 79(3):276-82. DOI: 10.1016/j.lungcan.2012.11.022. View

20.

Park K, Tan E, OByrne K, Zhang L, Boyer M, Mok T . Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016; 17(5):577-89. DOI: 10.1016/S1470-2045(16)30033-X. View